Eyam partners with pharmaceutical and global-health leaders to bring durable, non-viral, redosable genetic medicines to patients. We have capacity for one new platform partnership in 2026.
| Model | Structure | Best for |
|---|---|---|
| Feasibility study | Milestone-gated with option-to-license; can be structured as an MTA or non-commercial licensing agreement | Evaluate Gemini against your proprietary program. Eyam runs the assays. |
| Platform license | By indication / geography; tiered royalties | Apply Gemini to your therapeutic area at scale. |
| Co-development | Joint R&D | Combine your clinical/regulatory engine with Gemini delivery. |
| Product license | IND-directed asset | In-license a de-risked program (e.g., CaV1.4 oncology). |
Validated in Nature Communications (2025) — not speculative.
Programs partnered with Medicines for Malaria Venture; 6+ month expression demonstrated.
Validated in mouse, canine, and pig; NHP studies underway.
Non-viral, non-nanoparticle — designed to be redosed as needed.
18 platform patents, with more in active prosecution.
Feasibility, platform, product, or co-development.
Tell us about your program or therapeutic area and we'll set up an introductory call under NDA.
Capacity for one new platform partnership in 2026.
Email our BD team →